Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
Merck emphasized the broader significance of the findings
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Subscribe To Our Newsletter & Stay Updated
